All the Drug Class Drugs
Colony Stimulating Factor. Lipegfilgrastim 6 mg / 0.6 ml. PREFILLED SYRINGE (sol. for inj.): 1 × 0.6
ml. One 6 mg dose of (a single pref.
syr.) for each chemoth. cycle, given approx. 24 hrs. after cytotoxic
chemoth.
Reduct. in the durat. of neutropenia and
the incidence of febrile neutropenia in
adult pts. treated with cytotoxic
chemother. for malignan. (with the
except. of chron. myeloid leukaemia and
myelodysplast. syndr.)
C/I: Hypersens.
Colony Stimulating Factor. Pegfilgrastim 6 mg / 0.6 ml. PREFILL SYRINGE (ready-to-use) 1 x 6
mg/0.06 ml. One 6 mg dose for ea.
chemother. cycle S.C. inject. approx.
24 hrs follow. cytotox. chemother.
Reduct. durat. neutropen., incidence of
febrile neutropen. in pts. treated with cytotox. chemother. for malignancy (with
the except. of chron. myeloid leukem. and
myelodysplast. synds.)
C/I: Hyperens.
Colony Stimulating Factor. Filgrastim 30 MU/ml (0.3 mg/ml), 30 MU/0.5 ml (0.6 mg/ml), 48 MU/0.5 ml (0.96 mg/ml). VIALS (sol. for inj.): 5×30MU (0.3 mg/
ml).
PREF. SYR. (sol. for inj.): 5×30MU (0.6 mg/
ml), 1, 5×48MU (0.96 mg/ml). Dosage ajust. individ. accord. pt. med. condition.
Reduct. in the duration of neutropenia and
the incidence of febrile neutropenia in pts.
treated with established cytotoxic
chemother. for malign. (with the exception
of chronic myeloid leukaemia and
myelodysplastic syndr.) and for the reduct.
in the duration of neutropenia in pts.
undergoing myeloablative ther. followed
by bone marrow transplant., considered
to be at incr. risk of prolon. severe
neutropenia. The safety and efficacy of
Filgrastim are similar in adults and child.
receiving cytotoxic chemother. Indic. for
the mobilisation of peripheral blood
progenitor cells (PBPCs). In pts., children/
adults, with severe congen., cyclic or
idiopathic neutropenia with an ANC of
≤0.5 ×10^9/l, and a history of severe or
recurrent infec., long-term admin. of this
drug is indicated to increase neutrophil
counts and to reduce the incidence and
duration of infect.-related events.
C/I: Hypersens.
Colony Stimulating Factor. Pegfilgrastim 6 mg / 0.6 ml. PREFILL. SYR.: 1 x 6 mg / 0.6 mL. One 6 mg for ea. chemother. cycle, S.C. inject. at least 24 hrs. after cytotox. chemother. See lit.
Reduct. durat. neutropen., incidence of febrile neutropen. in pts. treat. with cytotox. chemother.at interval. of 14 dys. or more, for malignan. (with the exception of chronic myeloid leukemia and myelodysplastic synd.).
C/I: Hypersens.
Colony Stimulating Factor. Filgrastim 300 mcg/0.5 ml, 480mcg/0.5ml. PREF.SYR. (sol. for inj. or infus.):1,3,5,10×. Dosage ajust. individ. accord. pt. med. condition.
Indicated for the reduct. in the duration of neutropen. and the incidence of febrile neutropen. in pts. treated with established cytotoxic chemother. for malignan. (with the exception of chronic myeloid leukaem. and myelodysplastic syndr.) and for the reduc. in the duration of neutropen. in pts. underg. myeloablative therapy followed by bone marrow transplantat. consid.to be at incr. risk of prolong. severe neutropen. The safety and efficacy of StimoFil are similar in adults and child. receiv. cytotox. chemother.
Indic. for the mobilisation of peripher. blood progenitor cells (PBPCs).
In pts., child. or adult. with severe congenit., cyclic, or idiopath. neutropen. with an absolute neutrophil count (ANC) of ≤ 0.5 x 109 /L, and a history of severe or recur. infections, long term admin. of StimoFil is indic.to incr. neutrophil counts and to reduce the incidence and durat. of infec.-related events.
Tmt. of persist. neutropen. (ANC less than or equal to 1.0 x 109/L) in pts. with advanced HIV infec., in order to reduce the risk of bacter. infections when other options to manage neutropen. are inappropr.
